Precision BioSciences
Develops ARCUS-based in vivo gene-editing therapies.
Something off on this page? Send us feedback.
Profile
Develops ARCUS-based in vivo therapies, with PBGENE-HBV and PBGENE-DMD as lead clinical-stage programs. Its single operating segment focuses on therapeutics following the food-and-agriculture spin-out; Imugene holds global rights to azer-cel and conducts its clinical execution.
Built around the ARCUS gene-editing platform, the company discovers and develops in vivo therapies. Lead clinical-stage programs include PBGENE-HBV and PBGENE-DMD. These programs reflect the company’s narrowed in vivo therapeutic focus.
Operating as a single segment, it concentrates on therapeutic uses of ARCUS, including gene insertion, excision, and elimination. The platform derives from a natural homing endonuclease. Early platform work included crop plants such as corn, soybeans, and cotton.
The food-and-agriculture business was spun out as Elo Life Systems, while clinical execution of the azer-cel cancer program moved to Imugene. When the Prevail collaboration ended, programs returned for independent development or new partnerships.
Company facts
Key statistics
Year to date +89.8% · Average volume (30d) 280.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jun 9, 2026 | Oppenheimer | Target | $20 | ||
| Mar 13, 2026 | Jefferies | Target | $19 | ||
| Jan 10, 2025 | BMO Capital | Upgrade | Market Perform | Outperform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.80 | −$1.26 | −56.7% | $740.0K | $0 | −100.0% | −0.67% |
| May 5, 2026Q1 FY26 | −$0.27 | −$0.34 | −25.9% | $4.1M | $10.8M | +167.6% | +0.94% |
| Mar 12, 2026Q4 FY25 | −$0.21 | $0.36 | +271.4% | $9.1M | $34.2M | +276.9% | 0.00% |
| Nov 3, 2025Q3 FY25 | −$0.31 | −$1.84 | −493.5% | $9.1M | $13.0K | −99.9% | −9.10% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $29.0K | $18.0K | $13.0K | $34.2M | $10.8M | $0 | |
| Gross profit | $29.0K | $18.0K | $13.0K | $34.2M | $10.8M | $0 | |
| Operating income | −$22.1M | −$21.9M | −$20.7M | $12.5M | −$9.1M | −$19.2M | |
| Net income | −$20.6M | −$23.5M | −$21.8M | $20.1M | −$18.4M | −$32.7M | |
| Diluted EPS | −$2.29 | −$2.13 | −$1.84 | $1.05 | −$0.75 | −$1.26 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | |
| Operating margin | -76,248.3% | -121,538.9% | -158,976.9% | 36.6% | -83.7% | — |
Fiscal years (4-quarter sums)FY21 $115.5M · FY22 $25.1M · FY23 $48.7M · FY24 $68.7M · FY25 $34.3M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $87.5M · Total debt $28.1M · Total assets $125.9M · Shareholders' equity $45.3M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 12.83M · Float 9.85M · 76.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 2.24M | 17.44% | 13F | May 15, 2026 |
| Abrdn PLC | 2.23M | 17.39% | 13F | Apr 29, 2026 |
| Aberdeen Group plc | 2.14M | 8.88% | 13G | Jan 27, 2026 |
| Empery Asset Management, LP | 1.97M | 7.63% | 13G | Apr 15, 2026 |
| Bleichroeder LP | 1.66M | 12.96% | 13F | May 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | J. Jefferson Smith | officer: Chief Research Officer | −4,925 | $3.84 |
| Feb 18, 2026 | Dario Scimeca | officer: General Counsel and Secretary | −4,925 | $3.84 |
| Feb 18, 2026 | John Alexander Kelly | officer: Chief Financial Officer | −8,149 | $3.84 |
| Feb 18, 2026 | Michael Amoroso | director, officer: President and CEO | −20,559 | $3.84 |
| Jan 21, 2026 | J. Jefferson Smith | officer: Chief Research Officer | −10,200 | $4.03 |
Peers
- Sarepta Therapeutics
DMD genetic-medicine rivalry through ELEVIDYS
- Intellia Therapeutics
In vivo CRISPR liver editing with late-stage programs
- CRISPR Therapeutics
LNP-enabled in vivo liver gene-editing programs
- Dyne Therapeutics
DMD rivalry through exon-skipping therapies
- Editas Medicine
In vivo CRISPR development for one-time therapies
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Precision BioSciences | $7.85 | +0.90% | $99.8M | — | — | 2.2 | −100.0% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Dyne Therapeutics | $25.07 | −0.04% | $4.68B | — | — | — | — |
| Editas Medicine | $3.14 | −0.30% | $484.9M | — | — | 10.3 | +232.3% |
| Median | — | 26.3 | 20.3 | +99.0% |